Baricitinib-d3

• Description:

  Baricitinib-d3 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

• Product Name Alternative:

  LY3009104-d3; INCB028050-d3

• UNSPSC:

  12352005

• Target:

  JAK

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research:

  Inflammation/Immunology

• Purity:

  99.0

• Solubility:

  10 mM in DMSO

• Smiles:

  N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC([2H])([2H])[2H])=O)C1

• Molecular Formula:

  C16H14D3N7O2S

• Molecular Weight:

  374.44

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184 (9) :5298-307.|[3]Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2 (4) :351-5.|[4]Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond) . 2015 Nov;39 (11) :1607-18.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1564242-30-3]